Catamaran Bio
Executivos
Veja o organograma con seus 12 executivos principais
Biografias mais buscadas da Catamaran Bio
- Alvin Shih, Chief Executive Officer and Director
- Kevin Pojasek, Director
- Frank Lee, Chairman of the Board
Criar um alerta
para seguir os movimentos de executivos da Catamaran Bio.
Biotecnologia
Catamaran Bio possui 2.295 concorrentes concorrentes Lonza (Suíça), Eurofins (Luxemburgo) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Johnson & Johnson has announced the acquisition of Proteologix (publicado em 20 de maio de 2024).
- Rapport Therapeutics acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 20 de maio de 2024).
- Lycia Therapeutics acaba de anunciar uma arrecadação de fundos de 107 milhões de dólares. (publicado em 15 de maio de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Catamaran Bio
- Catamaran Bio Announces Preclinical Data from Allogeneic CAR-NK Cell Therapy Pipeline for Solid Tumors to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Catamaran Bio
- Catamaran Bio selects OmniaBio as partner to develop and manufacture allogeneic CAR-NK cell therapies - Catamaran Bio
- MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs - Catamaran Bio
- Catamaran Bio Presents Preclinical Efficacy Data for Two Allogeneic CAR-NK Cell Therapies for Solid Tumors at SITC 2022 Annual Meeting - Catamaran Bio
- Catamaran Bio to Present Preclinical Efficacy Data for Allogeneic CAR NK Cell Therapies to Treat Solid Tumors at SITC Annual Meeting - Catamaran Bio
- Catamaran Bio Presents Preclinical Data Supporting Novel Engineered CAR-NK Cell Therapies For Treating Solid Tumors - Catamaran Bio
- Catamaran Bio to Present Preclinical Data at ASGCT Annual Meeting to Support CAR-NK Approach for Solid Tumors - Catamaran Bio
- Catamaran Bio Appoints Cherry Thomas, MD, as Chief Medical Officer - Catamaran Bio
- Catamaran Bio Presents Preclinical In Vivo Efficacy Data Supporting Advancement of CAT 179, a HER2-targeted Allogeneic CAR-NK Cell Therapy - Catamaran Bio
- Catamaran Bio Appoints Frank Lee as Chair of its Board of Directors - Catamaran Bio
- View more press releases Close
Redes sociais sobre Catamaran Bio
- Catamaran Bio na Wikipedia, Google News e Yahoo Finance
- Catamaran Bio na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Alvin Shih 
Ligue para a Catamaran Bio em +1 914...
